Venture&Growth Archives - Gilde Healthcare

Menu
Menu
Home

Neuigkeiten & Einblicke
Venture&Growth

Gilde Healthcare company SpliceBio announces first patient dosed in Phase 1/2 ASTRA study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease   SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced that it has dosed the first...
13. März 2025

Gilde Healthcare participates in $65 Million financing of Microtransponder to enhance Vivistim adoption for Chronic Stroke Recovery

test MicroTransponder®, Inc, today announces a $65 million Series F financing round. MicroTransponder is a fast growing commercial stage stroke company with the FDA-approved Vivistim® Paired VNS™ System. Gilde Healthcare joins the round as new investor, together with Longitude Capital. Existing investors include US Venture Partners (USVP), Osage University Partners, Action Potential Venture Capital, GPG Ventures, […]

Gilde Healthcare Company Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

test Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today announces the appointment of Haseeb Ahmad as its Chief Executive Officer and member of the Board of Directors effective immediately. Haseeb has been appointed to steer Purespring through a critical phase of development and growth. He brings significant senior industry leadership, […]

Gilde Healthcare company Shoulder Innovations Announces Closing of $40 Million Series E Equity Financing

Shoulder Innovations, a leader in shoulder replacement technology, today announced the closing of a $40 million Series E equity financing round. The financing was led by existing investor U.S. Venture Partners (USVP), with support from additional existing investors including Gilde Healthcare Partners, Gilmartin Capital, and Aperture Venture...

Gilde Healthcare company GT Medical Technologies raises $37 million in to advance GammaTile® for patients with operable brain tumors

GT Medical Technologies, Inc. (GT MedTech), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced the company has completed a $37 million first close of a Series D financing round. The financing was led by Evidity Health...

Alleviant Medical Secures $90 Million Financing to Expand Interventional Heart Failure Pivotal Trial Program

Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, today announced a $90 million financing to fund its second pivotal trial. Led by Gilde Healthcare, the round also adds Omega Funds and includes participation from existing shareholders S3 Ventures, RiverVest...

Gilde Healthcare company FIRE1 raises $120 Million Financing to Revolutionize Heart Failure Care

Gilde Healthcare company FIRE1, announced the completion of a $120 million financing round led by new investors Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and existing investors Gilde Healthcare, Andera Partners, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures,...

Gilde Healthcare portfolio company SpliceBio Announces U.S. FDA IND Clearance of SB-007

SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored natural history study...

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 million (approx. USD 147 million)....
Loading...
These were all messages
914634ee73